The DOI matches its Crossref record; 19 of the 19 references it cites were found in a registry or an index.
Pharmacokinetics and Safety of Intravenous Voriconazole in Children after Single- or Multiple-Dose Administration
Open accessAbstract
We conducted a multicenter study of the safety, tolerability, and plasma pharmacokinetics of the parenteral formulation of voriconazole in immunocompromised pediatric patients (2 to 11 years old). Single doses of 3 or 4 mg/kg of body weight were administered to six and five children, respectively. In the multiple-dose study, 28 patients received loading doses of 6 mg/kg every 12 h on day 1, followed by 3 mg/kg every 12 h on day 2 to day 4 and 4 mg/kg every 12 h on day 4 to day 8. Standard population pharmacokinetic approaches and generalized additive modeling were used to construct the structural pharmacokinetic and covariate models used in this analysis. In contrast to that in adult healthy volunteers, elimination of voriconazole was linear in children following doses of 3 and 4 mg/kg every 12 h. Body weight was more influential than age in accounting for the observed variability in voriconazole pharmacokinetics. Elimination capacity correlated with the CYP2C19 genotype. Exposures were similar at 4 mg/kg every 12 h in children (median area under the concentration-time curve (AUC), 14,227 ng · h/ml) and 3 mg/kg in adults (median AUC, 13,855 ng · h/ml). Visual disturbances occurred in 5 (12.8%) of the 39 patients and were the only drug-related adverse events that occurred more than once. No withdrawals from the study were related to voriconazole. We conclude that pediatric patients have a higher capacity for elimination of voriconazole per kilogram of body weight than do adult healthy volunteers and that dosages of 4 mg/kg may be required in children to achieve exposures consistent with those in adults following dosages of 3 mg/kg.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Modern Applied Statistics with S
Venables, W. N., & Ripley, B. D. (2002) · Statistics and Computing · doi:10.1007/978-0-387-21706-2 · Cited by 24,305
Voriconazole versus Amphotericin B for Primary Therapy of Invasive Aspergillosis
Herbrecht, R., Denning, D. W., Patterson, T. F., Bennett, J. E., Greene, R. E., Oestmann, J.-W., Kern, W. V., Marr, K. A., Ribaud, P., Lortholary, O., et al. (2002) · New England Journal of Medicine · doi:10.1056/nejmoa020191 · Cited by 3,304
Chronic Granulomatous Disease: Report on a National Registry of 368 Patients
Winkelstein, J. A., Marino, M. C., Johnston, R. B., Boyle, J., Curnutte, J., Gallin, J. I., Malech, H. L., Holland, S. M., Ochs, H., Quie, P., et al. (2000) · Medicine · doi:10.1097/00005792-200005000-00003 · Cited by 1,728
Current and emerging azole antifungal agents
Sheehan, D. J., Hitchcock, C. A., & Sibley, C. M. (1999) · Clinical Microbiology Reviews · doi:10.1128/cmr.12.1.40 · Cited by 1,137
Xpose—an S-PLUS based population pharmacokinetic/pharmacodynamic model building aid for NONMEM
Jonsson, E. N., & Karlsson, M. O. (1998) · Computer Methods and Programs in Biomedicine · doi:10.1016/s0169-2607(98)00067-4 · Cited by 1,002
Self-citationWalsh, T. J., Pappas, P., Winston, D. J., Lazarus, H. M., Petersen, F., Raffalli, J., Yanovich, S., Stiff, P., Greenberg, R., Donowitz, G., et al. (2002) · New England Journal of Medicine · doi:10.1056/nejm200201243460403 · Cited by 979
Self-citationModern Applied Statistics with S-PLUS
Venables, W. N., & Ripley, B. D. (1999) · Statistics and Computing · doi:10.1007/978-1-4757-3121-7 · Cited by 978
Efficacy and safety of voriconazole in the treatment of acute invasive aspergillosis
Denning, D. W., Ribaud, P., Milpied, N., Caillot, D., Herbrecht, R., Thiel, E., Haas, A., Ruhnke, M., & Lode, H. (2002) · Clinical Infectious Diseases · doi:10.1086/324620 · Cited by 844 · cited 1×
“Several studies of voriconazole found that the most distinctive visual reaction to the drug is an altered or enhanced perception of light (2, 5, 9, 18, 19).”
BackgroundDrugs and the Pharmaceutical Sciences
(2010) · Drugs and the pharmaceutical sciences · doi:10.1201/ihcdruphasci · Cited by 586
Biochemistry and molecular biology of the human CYP2C subfamily
Goldstein, J. A., & de Morais, S. M. F. (1994) · Pharmacogenetics · doi:10.1097/00008571-199412000-00001 · Cited by 529
WALSH, T. J., LUTSAR, I., DRISCOLL, T., DUPONT, B., RODEN, M., GHAHRAMANI, P., HODGES, M., GROLL, A. H., & PERFECT, J. R. (2002) · The Pediatric Infectious Disease Journal · doi:10.1097/00006454-200203000-00015 · Cited by 431
Self-citationAlly, R., Schürmann, D., Kreisel, W., Carosi, G., Aguirrebengoa, K., Dupont, B., Hodges, M., Troke, P., Romero, A. J., & the Esophageal Candidiasis Study Group (2001) · Clinical Infectious Diseases · doi:10.1086/322653 · Cited by 331
Andes, D., Marchillo, K., Stamstad, T., & Conklin, R. (2003) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.47.10.3165-3169.2003 · Cited by 231 · cited 2×
“Several studies of voriconazole found that the most distinctive visual reaction to the drug is an altered or enhanced perception of light ( 2 , 5, 9, 18, 19).”
BackgroundInfluentialLazarus, H. M., Blumer, J. L., Yanovich, S., Schlamm, H., & Romero, A. (2002) · Journal of Clinical Pharmacology · doi:10.1177/0091270002424005 · Cited by 179
Self-citationGroll, A. H., Kurz, M., Schneider, W., Witt, V., Schmidt, H., Schneider, M., & Schwabe, D. (1999) · Mycoses · doi:10.1046/j.1439-0507.1999.00496.x · Cited by 149
New Drugs and Novel Targets for Treatment of Invasive Fungal Infections in Patients with Cancer
Chiou, C. C., Groll, A. H., & Walsh, T. J. (2000) · The Oncologist · doi:10.1634/theoncologist.5-2-120 · Cited by 124
Self-citationNew investigational antifungal agents for treating invasive fungal infections
Hossain, M. A., & Ghannoum, M. A. (2000) · Expert Opinion on Investigational Drugs · doi:10.1517/13543784.9.8.1797 · Cited by 94
Invasive fungal infections in children: recent advances in diagnosis and treatment.
Walsh, T. J., Gonzalez, C., Lyman, C. A., Chanock, S. J., & Pizzo, P. A. (1996) · PubMed · Cited by 93
Self-citationInvasive aspergillosis in human immunodeficiency virus-infected children
Shetty, D., Giri, N., Gonzalez, C. E., Pizzo, P. A., & WALSH, T. J. (1997) · The Pediatric Infectious Disease Journal · doi:10.1097/00006454-199702000-00010 · Cited by 89
Self-citation
Cited by
Pappas, P. G., Kauffman, C. A., Andes, D. R., Clancy, C. J., Marr, K. A., Ostrosky-Zeichner, L., Reboli, A. C., Schuster, M. G., Vazquez, J. A., Walsh, T. J., et al. (2016) · Clinical Infectious Diseases · doi:10.1093/cid/civ933 · Cited by 4,200
Self-citationPappas, P. G., Kauffman, C. A., Andes, D., Benjamin, D. K., Calandra, T. F., Edwards, J. E., Filler, S. G., Fisher, J. F., Kullberg, B.-J., Zeichner, L. O., et al. (2009) · Clinical Infectious Diseases · doi:10.1086/596757 · Cited by 3,191
“adults [68], demonstrating linear elimination in children after”
BackgroundSelf-citationPatterson, T. F., Thompson, G. R., Denning, D. W., Fishman, J. A., Hadley, S., Herbrecht, R., Kontoyiannis, D. P., Marr, K. A., Morrison, V. A., Nguyen, M. H., et al. (2016) · Clinical Infectious Diseases · doi:10.1093/cid/ciw326 · Cited by 2,926
Self-citationWalsh, T. J., Anaissie, E. J., Denning, D. W., Herbrecht, R., Kontoyiannis, D. P., Marr, K. A., Morrison, V. A., Segal, B. H., Steinbach, W. J., Stevens, D. A., et al. (2008) · Clinical Infectious Diseases · doi:10.1086/525258 · Cited by 2,706
Self-citationUllmann, A. J., Aguado, J. M., Arikan-Akdagli, S., Denning, D. W., Groll, A. H., Lagrou, K., Lass-Flörl, C., Lewis, R. E., Munoz, P., Verweij, P. E., et al. (2018) · Clinical Microbiology and Infection · doi:10.1016/j.cmi.2018.01.002 · Cited by 1,556
Metadata
- Authors
- Walsh, T. J., Karlsson, M. O., Driscoll, T., Arguedas, A. G., Adamson, P., Saez-Llorens, X., Vora, A. J., Arrieta, A. C., Blumer, J., Lutsar, I., Milligan, P., & Wood, N.
- Venue
- Antimicrobial Agents and Chemotherapy
- Publisher
- American Society for Microbiology
- Published
- 2004-06
- Volume
- 48
- Issue
- 6
- Pages
- 2166-2172
- ISSN
- 0066-4804 (ISSN-L)
- 1098-6596
- OpenAlex
- W2102934589
- Cited by
- 335
- References
- 19
- FWCI
- 15.90
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.